NAD+ and its precursor NMN are among the most actively researched compounds in longevity science, with a growing human clinical evidence base. Here is an honest guide to what the research shows and what proper access looks like in Australia.
This article is for general educational purposes only and does not constitute medical advice. Therapeutic NAD+ and NMN products require assessment from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
NAD+ and NMN occupy a unique position in the longevity and health optimisation space because they have attracted more mainstream scientific attention, more human clinical trial data, and more prominent researchers than almost any other compounds in this category. Understanding what the research actually shows - and what the honest limitations of that evidence are - is important for anyone evaluating whether these compounds are appropriate for them.
NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme found in every cell of the body, where it plays an essential role in cellular energy metabolism - specifically in the processes that generate ATP from the nutrients we consume. Beyond energy production, NAD+ is required by a class of enzymes called sirtuins, which are involved in DNA repair, gene expression regulation, and cellular stress responses that are central to healthy ageing.
NAD+ levels decline progressively with age, typically by around half between young adulthood and middle age in many tissues. This decline has been associated with reduced mitochondrial function, impaired DNA repair capacity, and reduced sirtuin activity - all of which are relevant to the biology of ageing. The research interest in NAD+ restoration is grounded in this well-characterised age-related decline and its mechanistic connections to multiple ageing pathways.
NMN stands for nicotinamide mononucleotide. It is a precursor molecule that the body uses to synthesise NAD+. The rationale for using NMN rather than NAD+ directly relates to bioavailability. NAD+ itself does not easily cross cell membranes, while NMN can enter cells and be converted to NAD+ internally. Research examining NAD+ restoration has therefore focused substantially on precursor supplementation, with NMN and nicotinamide riboside being the most studied precursors.
The human clinical evidence for NMN and related NAD+ precursors is more developed than for most compounds in the health optimisation space. Multiple human clinical trials have now been published examining the effects of NMN supplementation on NAD+ levels, metabolic markers, physical performance, and various ageing-related parameters. This places the compound in a different evidential category from compounds supported primarily by preclinical research.
The human trial data generally supports the ability of NMN supplementation to increase NAD+ levels in various tissues, which is the mechanistic first step for the downstream effects of interest. The evidence for downstream effects on metabolism, physical performance, and other longevity-relevant outcomes is more mixed and continues to develop as trials with longer timeframes and larger populations are completed.
NAD+ and exercise: Research has examined the interaction between NAD+ levels, exercise capacity, and muscle function. Some human trial data has specifically examined NMN's effects on physical performance markers in older adults, which is one of the more clinically meaningful endpoints given the known relationship between muscle function, metabolic health, and longevity outcomes.
NAD+ itself does not easily cross cell membranes, which limits the effectiveness of direct NAD+ supplementation for raising intracellular NAD+ levels. NMN is a precursor that enters cells through specific transporters and is then converted to NAD+ inside the cell, allowing for more effective intracellular NAD+ restoration. Injectable NAD+ bypasses some of this limitation through different delivery mechanisms.
The specific approach most appropriate for any individual - whether injectable NAD+, oral NMN, or a combination - is a clinical decision made by the prescribing doctor based on that person's circumstances and goals.
Lower-dose oral NMN supplements are available from health food retailers in Australia. The therapeutic formulations available through licensed compounding pharmacies following a medical assessment differ from these over-the-counter products in terms of concentration, form, and the clinical oversight involved. Whether a therapeutic approach is appropriate for any individual is determined by a prescribing doctor rather than by self-directed supplementation.